

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10533906	
	Filing Date		2001-05-11	
	First Named Inventor	Maecke		
	Art Unit	NA		
	Examiner Name	NA		
Attorney Docket Number		3025-107		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.		T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10533906
Filing Date		2001-05-11
First Named Inventor	Maecke	
Art Unit	NA	
Examiner Name	NA	
Attorney Docket Number	3025-107	

1	Heppeler, A. et al.: "Radiometal-labelled macrocyclic chelator-derivatized somatostatin analogs with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy" in Chem. -Eur. J., 1999, 5(7), 1974-1981	<input type="checkbox"/>
2	Eisenwiener, K.-P. et al.: "Synthesis and peptide coupling of a new DOTA-based prochelator, forming neutral complexes with Yttrium-90 and Indium-111." in Journal of Labelled Compounds and Radiopharmaceuticals, vol.44, 2001-05, no. Supplement 1, pp.:S694-S696. Print. Meeting info.: Fourteenth International Symposium on Radiopharmaceutical Chemistry Interlaken, Switzerland, June 10-15, 2001	<input type="checkbox"/>
3	Eisenwiener, K.-P. et al.: "A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling" in Bioorganic & Medicinal Chemistry Letters, 2000, vol.10, no.18, pp.:2133-2135	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.